T-cell engagers have emerged as an important class of bispecific and multispecific immunotherapeutic agents capable of physically bridging cytotoxic T cells directly to malignant cells, yet their therapeutic performance within solid tumors faces substantial biological constraints. While these engineered molecular formats have produced verified clinical successes across several hematological malignancies, their direct translation to solid oncology continues to be impeded by dense physical stroma, a profoundly immunosuppressive local microenvironment, pronounced tumor-associated antigen heterogeneity, and dangerous on-target, off-tumor toxicities. In a comprehensive scientific analysis published in Biomarker Research, investigators led by Jiani Li, Mengmeng Zhu, and colleagues systematically evaluated the emerging molecular architectures, pharmacokinetic modifications, and delivery vectors designed to overcome these historical clinical limitations.
Unlike conventional immune checkpoint inhibitors that rely fundamentally on intact endogenous antigen processing and presentation pathways, T-cell engagers bypass the major histocompatibility complex machinery altogether. Physiological T-cell activation typically requires antigen processing by specialized antigen-presenting cells, presentation via major histocompatibility complex molecules for recognition by the T-cell receptor, and coordinated secondary costimulatory signals. Malignant cells routinely evade this pathway by downregulating major histocompatibility complex expression, losing specific antigens, and establishing an immunosuppressive local niche. T-cell engagers circumvent this limitation by simultaneously binding the invariant CD3 subunit of the T-cell receptor complex and a designated tumor-associated antigen on the cancer cell surface. This forced proximity triggers immune synapse assembly, CD3 crosslinking, and the rapid release of cytotoxic effector molecules, including perforin, granzymes such as granzyme B, tumor necrosis factor-alpha, interferon-gamma, and interleukin-2, driving targeted tumor cell lysis.
Despite this potent cytotoxic mechanism, conventional full-length bispecific immunoglobulins have an approximate molecular weight of 150 kilodaltons, which restricts their physical diffusion into dense solid tumor parenchyma. Components of the extracellular matrix and cancer-associated fibroblasts establish dense stromal barriers that readily trap large therapeutic proteins, preventing them from achieving therapeutic interstitial concentrations. To overcome these transport barriers, bioengineers have developed miniaturized formats such as bispecific T-cell engagers, dual-affinity re-targeting molecules, and single-domain camelid-derived heavy-chain variable domain antibodies. Tandem single-chain variable fragment constructs, exemplified by the 55-kilodalton bispecific T-cell engager platform, exhibit substantially enhanced interstitial penetration into deep tumor beds. However, these compact proteins frequently suffer from limited conformational stability and rapid renal clearance, which shortens their systemic circulation half-life and complicates long-term dosing.
To mitigate the rapid elimination of miniaturized designs, several pharmacokinetic optimization approaches have been integrated into next-generation formats. Classical Fc-fusion platforms, such as the extended half-life bispecific design utilized in tarlatamab, introduce an effector-silenced Fc domain that reduces renal filtration through increased hydrodynamic volume and exploits neonatal Fc receptor-mediated recycling pathways. In clinical evaluations involving patients with extensive-stage small-cell lung cancer, tarlatamab exhibited a mean terminal elimination half-life of 5.8 days, supporting an every-two-week administration regimen. Site-specific mutations within the CH2-CH3 domains, such as the YTE and LS modifications, have also been explored to fine-tune neonatal Fc receptor affinity. Alternatively, researchers have engineered albumin-binding domains derived from streptococcal protein G and anti-human serum albumin single-domain antibodies, as utilized in the TriTAC platform, to prolong systemic persistence without restoring the full, bulky immunoglobulin framework.
Beyond structural modifications to the recombinant proteins themselves, advanced non-viral and viral expression vehicles have been designed to achieve sustained in situ therapeutic protein generation directly within the tumor microenvironment. Lipid nanoparticles encapsulating messenger RNA encoding T-cell engagers have demonstrated the capacity to turn host tumor tissues into transient bioreactors following local or systemic administration. For instance, the investigational candidate MTS-105 employs liver-targeted lipid nanoparticles to deliver messenger RNA encoding a glypican-3 by CD3 construct, eliciting tumor clearance and immunological memory in preclinical hepatocellular carcinoma models.
A critical engineering consideration highlighted in the scientific review centers on the delicate balance between the binding affinities for CD3 and the target tumor-associated antigen. Early drug designs frequently prioritized maximal affinity for both arms, but clinical evaluations revealed that excessive CD3 affinity triggered intense cytokine release syndrome, early T-cell exhaustion, and extensive systemic toxicity. Cellular immunology studies have established that T-cell-directed cytotoxicity and proinflammatory cytokine secretion possess distinct signaling thresholds: target cell lysis can be achieved via relatively weak T-cell receptor engagement, whereas massive cytokine release requires stronger, prolonged receptor crosslinking. Modern engineering strategies therefore favor an asymmetric affinity profile combining high tumor-associated antigen affinity with moderate-to-low CD3 affinity, as exemplified by candidates like TNB-585, AMG 757, and NILK-2301, which anchor preferentially to malignant cells before initiating controlled effector activation.
To prevent off-target damage to normal tissues that express shared target antigens at low physiological levels, researchers have developed tumor microenvironment-responsive prodrug platforms. These conditionally activated constructs remain masked and pharmacologically inert throughout peripheral circulation, unmasking their binding arms only upon reaching the biochemical conditions of the tumor interstitium. Protease-cleavable designs, including the TRACTr and PRO-XTEN platforms, employ synthetic masking peptides, unstructured XTEN polypeptides, or anti-idiotypic antibody domains linked via substrates sensitive to tumor-overexpressed proteases. In clinical trials, masked candidates such as VIR-5818 and the prostate-specific membrane antigen-targeting VIR-5500 demonstrated reduced cytokine release while achieving significant biological activity, with VIR-5500 inducing PSA50 responses in over half of treated prostate cancer patients. Additional prodrug concepts utilize condition-dependent self-dissociation triggered by acidic intratumoral pH or split-molecule assemblies that reconstitute into active engagers exclusively at the disease site.
Solid tumors also present profound target antigen heterogeneity and antigen-loss-mediated immune escape mechanisms that frequently overcome monovalent recognition. To resolve these escape pathways, engineers have constructed bivalent two-plus-one molecular architectures that incorporate two tumor-antigen-binding domains alongside a single CD3-binding domain, thereby maximizing avidity against tumor cells exhibiting low target density while sparing healthy tissues. Broadening this strategy even further, soluble T-cell receptor-based engagers, such as tebentafusp, target intracellular peptide antigens presented by specific human leukocyte antigen molecules, opening an expansive repertoire of tumor-specific intracellular oncoproteins that cannot be accessed by traditional surface-directed antibodies. Finally, hybrid T-cell engager-drug conjugates, which integrate topoisomerase I inhibitors or related cytotoxic payloads into bispecific backbones, exploit bystander killing to eradicate neighboring antigen-negative malignant clones.
The review authors emphasize that future clinical success will depend heavily on biomarker-guided integration frameworks rather than merely stacking functional modules onto a single therapeutic protein. Baseline patient selection must incorporate quantitative measurements of target antigen density, human leukocyte antigen genotypes, intratumoral T-cell infiltration, and spatial microenvironmental characteristics rather than relying strictly on binary positive or negative designations. Furthermore, dynamic monitoring of peripheral cytokines, circulating tumor DNA alterations, and secondary resistance markers will be critical for tailoring intervention strategies. At the same time, the investigators caution that advanced engineering must remain tightly aligned with developability and manufacturing constraints, as intricate multispecific assemblies often suffer from low expression titers, high aggregation propensity, and poor stability during clinical translation.
Beyond primary TCR activation, integrating costimulatory domains has emerged as a strategy to prevent functional exhaustion in solid tumors, though early candidates revealed notable safety and translational hurdles. Trispecific antibodies engineered on Sanofi’s CODV-Ig platform, such as the CD3, CD28, and tumor-antigen-directed construct SAR443216, aimed to provide coordinated dual signaling to drive sustained T-cell proliferation. However, unrestrained crosslinking between adjacent T cells caused severe systemic immune hyperactivation, and clinical evaluation at ESMO 2024 demonstrated substantial toxicity without objective responses. To enforce tumor-dependent activation, alternative designs have introduced obligate cis-binding mechanisms, as seen in Zymeworks’ DLL3-directed TriTCE Co-Costim candidate ZW209, or competitive binding Fab arms, exemplified by the CLDN6-targeting molecule SAIL66. Nevertheless, clinical development of SAIL66 was halted after Phase I testing showed high anti-drug antibody rates and an absence of tumor responses. Concurrently, molecular architectures combining CD3 engagement with immune checkpoint blockade, such as Huiyu Pharmaceutical’s mesothelin-directed trispecific molecule HY05350, seek to simultaneously redirect cytotoxic lymphocytes and relieve local immunosuppression.
Expanding the therapeutic scope against heterogeneous lesions, clinical-stage TCR-TCE pipelines are translating intracellular antigen targeting across several solid tumor indications. Immatics has advanced its half-life-extended TCER platform, which incorporates low-affinity CD3 domains and silenced Fc regions; its candidates IMA401, targeting MAGEA4/8, and IMA402, targeting PRAME, completed Phase I escalation, with IMA402 progressing into Phase Ib expansion. In 2026, Repertoire dosed the first patient with RPTR-1-201, a TCR-TCE targeting a pan-tumor epitope that received Fast Track designation for triple-negative breast cancer, while Corregene initiated global multicenter Phase I evaluation of the MAGE-A1-directed construct CRPA1A2. In parallel, dual-action T-cell engager-drug conjugates have entered development to overcome complete antigen loss through payload-mediated bystander elimination. Leads Biolabs established its ImBiTDC platform with LBL-058, which conjugates a DLL3-directed bispecific antibody to a topoisomerase I inhibitor, and LBL-054, targeting gastrointestinal CDH17. Complementing this, Veleads designed VBC229, fusing a topoisomerase I inhibitor to a bivalent DLL3 engager with low CD3 affinity to expand the therapeutic window beyond approved agents.
Subject of Research: Engineering strategies and translational frameworks for T-cell engagers in solid tumors
Article Title: Innovative engineering strategies for T-cell engagers in solid tumors: from molecular design to clinical translation
Article References: Li, J., Zhu, M., Zhang, Y., Gao, Z., Qian, C., & Shan, J. (2026). Innovative engineering strategies for T-cell engagers in solid tumors: from molecular design to clinical translation. Biomarker Research, 14(1), Article 165. https://doi.org/10.1186/s40364-026-01042-7
Image Credits: AI Generated
DOI: 10.1186/s40364-026-01042-7
Keywords: T-cell engagers, solid tumors, bispecific antibodies, immunotherapy, tumor microenvironment, prodrug TCEs, antigen heterogeneity, T-cell receptor engagers, tarlatamab, blinatumomab, cytokine release syndrome, antibody engineering, half-life extension, nanoparticle delivery, oncolytic viruses, developability
